AbbVie Surges 0.3% on Earnings and Acquisition Hopes as $1.2B Volume Hits Top 500 Rank

On August 11, 2025, AbbVie (ABBV) closed with a 0.30% gain, trading at $198.64 as volume surged 47.69% to $1.20 billion. Key developments included positive Phase 3 trial results for a Genmab/AbbVie blood cancer therapy, which showed a 79% reduction in disease progression. The company also raised full-year profit guidance following a Q2 earnings beat driven by strong sales of Skyrizi and Rinvoq. Separately, AbbVie reported progress in talks to acquire Gilgamesh Pharmaceuticals for approximately $1 billion to expand its mental health therapeutics portfolio.

The Q2 earnings report highlighted resilience in AbbVie’s immunology and oncology segments, with adjusted diluted EPS rising 12.1% year-over-year. Analysts noted that the guidance increase signals confidence in offsetting Humira’s declining revenue. The Genmab collaboration underscores AbbVie’s focus on combination therapies, with subcutaneous epcoritamab showing robust efficacy in a pivotal trial. Meanwhile, the Gilgamesh acquisition aligns with AbbVie’s strategy to diversify into high-growth therapeutic areas.

A strategy of purchasing the top 500 high-volume stocks and holding for one day generated a 166.71% return from 2022 to the present, significantly outperforming the benchmark’s 29.18%. This highlights the role of liquidity concentration in short-term performance, particularly in volatile markets where high-volume stocks like AbbVie often exhibit pronounced price momentum.